Claudio Fiorino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2401068/publications.pdf

Version: 2024-02-01

214 papers 7,250 citations

43973 48 h-index 76769 74 g-index

217 all docs

 $\begin{array}{c} 217 \\ \text{docs citations} \end{array}$

times ranked

217

5347 citing authors

#	Article	IF	CITATIONS
1	Intra- and inter-observer variability in contouring prostate and seminal vesicles: implications for conformal treatment planning. Radiotherapy and Oncology, 1998, 47, 285-292.	0.3	321
2	Dose–volume effects for normal tissues in external radiotherapy: Pelvis. Radiotherapy and Oncology, 2009, 93, 153-167.	0.3	249
3	Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiotherapy and Oncology, 2002, 64, 1-12.	0.3	180
4	Rectal dose–volume constraints in high-dose radiotherapy of localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 2003, 57, 953-962.	0.4	177
5	Intensity-Modulated Proton Therapy Versus Helical Tomotherapy in Nasopharynx Cancer: Planning Comparison and NTCP Evaluation. International Journal of Radiation Oncology Biology Physics, 2008, 72, 589-596.	0.4	136
6	Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy. Radiotherapy and Oncology, 2006, 78, 276-282.	0.3	134
7	Clinical and Dosimetric Predictors of Late Rectal Syndrome After 3D-CRT for Localized Prostate Cancer: Preliminary Results of a Multicenter Prospective Study. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1130-1137.	0.4	132
8	IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiotherapy and Oncology, 2009, 93, 207-212.	0.3	126
9	Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6–70.2 Gy). International Journal of Radiation Oncology Biology Physics, 2003, 55, 688-694.	0.4	112
10	Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. European Urology, 2013, 63, 998-1008.	0.9	107
11	Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation. International Journal of Radiation Oncology Biology Physics, 2002, 52, 483-488.	0.4	103
12	Dosimetric Predictors of Laryngeal Edema. International Journal of Radiation Oncology Biology Physics, 2007, 68, 741-749.	0.4	102
13	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology, 2016, 69, 728-733.	0.9	102
14	Rectal and bladder motion during conformal radiotherapy after radical prostatectomy. Radiotherapy and Oncology, 2005, 74, 187-195.	0.3	96
15	Higher-than-expected Severe (Grade 3–4) Late Urinary Toxicity After Postprostatectomy Hypofractionated Radiotherapy: A Single-institution Analysis of 1176 Patients. European Urology, 2014, 66, 1024-1030.	0.9	94
16	Predictors for Rectal and Intestinal Acute Toxicities During Prostate Cancer High-Dose 3D-CRT: Results of a Prospective Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1401-1410.	0.4	91
17	Need for High Radiation Dose (≥70 Gy) in Early Postoperative Irradiation After Radical Prostatectomy: A Single-Institution Analysis of 334 High-Risk, Node-Negative Patients. International Journal of Radiation Oncology Biology Physics, 2009, 75, 966-974.	0.4	87
18	Significant reduction of acute toxicity following pelvic irradiation with Helical Tomotherapy in patients with localized prostate cancer. Radiotherapy and Oncology, 2007, 84, 164-170.	0.3	84

#	Article	IF	CITATIONS
19	Magnetic Resonance, Vendor-independent, Intensity Histogram Analysis Predicting Pathologic Complete Response After Radiochemotherapy of Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 765-774.	0.4	81
20	Texture analysis for the assessment of structural changes in parotid glands induced by radiotherapy. Radiotherapy and Oncology, 2013, 109, 384-387.	0.3	80
21	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. European Urology, 2017, 71, 886-893.	0.9	77
22	Predicting toxicity in radiotherapy for prostate cancer. Physica Medica, 2016, 32, 521-532.	0.4	75
23	Is the alpha–beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiotherapy and Oncology, 2005, 75, 74-82.	0.3	74
24	Emptying the rectum before treatment delivery limits the variations of rectal dose–volume parameters during 3DCRT of prostate cancer. Radiotherapy and Oncology, 2006, 80, 363-370.	0.3	74
25	Clinical Factors Predicting Late Severe Urinary Toxicity After Postoperative Radiotherapy for Prostate Carcinoma: A Single-Institute Analysis of 742 Patients. International Journal of Radiation Oncology Biology Physics, 2012, 82, 191-199.	0.4	74
26	The impact of contouring uncertainty on rectal 3D dose–volume data: Results of a dummy run in a multicenter trial (AIROPROS01–02). International Journal of Radiation Oncology Biology Physics, 2003, 57, 573-579.	0.4	73
27	CT-derived radiomic features to discriminate histologic characteristics of pancreatic neuroendocrine tumors. Radiologia Medica, 2021, 126, 745-760.	4.7	72
28	Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2001, 50, 651-658.	0.4	71
29	Evidence of Limited Motion of the Prostate by Carefully Emptying the Rectum as Assessed by Daily MVCT Image Guidance with Helical Tomotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 71, 611-617.	0.4	71
30	Dose–Volume Relationships for Acute Bowel Toxicity in Patients Treated With Pelvic Nodal Irradiation for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 29-35.	0.4	71
31	Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: Results of a large multicenter observational study. Radiotherapy and Oncology, 2009, 93, 197-202.	0.3	71
32	Set-up error in supine-positioned patients immobilized with two different modalities during conformal radiotherapy of prostate cancer. Radiotherapy and Oncology, 1998, 49, 133-141.	0.3	70
33	Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose–volume histograms and normal tissue complication probability. Radiotherapy and Oncology, 2002, 63, 249-255.	0.3	70
34	Development of a Set of Nomograms to Predict Acute Lower Gastrointestinal Toxicity for Prostate Cancer 3D-CRT. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1065-1073.	0.4	68
35	Dose–volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation. Radiotherapy and Oncology, 2016, 118, 79-84.	0.3	68
36	Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer. Radiotherapy and Oncology, 2011, 100, 124-130.	0.3	65

3

#	Article	IF	CITATIONS
37	Simultaneous Integrated Boost (SIB) for Nasopharynx Cancer with Helical Tomotherapy. Strahlentherapie Und Onkologie, 2007, 183, 497-505.	1.0	62
38	ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. Radiotherapy and Oncology, 2019, 141, 5-13.	0.3	62
39	Weekly Dose–Volume Parameters of Mucosa and Constrictor Muscles Predict the Use of Percutaneous Endoscopic Gastrostomy During Exclusive Intensity-Modulated Radiotherapy for Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 52-59.	0.4	61
40	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. European Urology, 2018, 73, 436-444.	0.9	60
41	Technologyâ€driven research for radiotherapy innovation. Molecular Oncology, 2020, 14, 1500-1513.	2.1	60
42	Artificial Intelligence in magnetic Resonance guided Radiotherapy: Medical and physical considerations on state of art and future perspectives. Physica Medica, 2021, 85, 175-191.	0.4	60
43	Phase I–II Study of Hypofractionated Simultaneous Integrated Boost With Tomotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 74, 392-398.	0.4	58
44	Dosimetry of Gamma Knife and linac-based radiosurgery using radiochromic and diode detectors. Physics in Medicine and Biology, 1999, 44, 887-897.	1.6	56
45	Treatment planning comparison between conformal radiotherapy and helical tomotherapy in the case of locally advanced-stage NSCLC. Radiotherapy and Oncology, 2008, 88, 310-318.	0.3	56
46	To Bleed or Not to Bleed. A Prediction Based on Individual Gene Profiling Combined With Dose–Volume Histogram Shapes in Prostate Cancer Patients Undergoing Three-Dimensional Conformal Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1431-1440.	0.4	55
47	Helical Tomotherapy vs. Intensity-Modulated Proton Therapy for Whole Pelvis Irradiation in High-Risk Prostate Cancer Patients: Dosimetric, Normal Tissue Complication Probability, and Generalized Equivalent Uniform Dose Analysis. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1589-1600.	0.4	54
48	Dose–volume and biological-model based comparison between helical tomotherapy and (inverse-planned) IMAT for prostate tumours. Radiotherapy and Oncology, 2008, 88, 34-45.	0.3	53
49	Quantifying the robustness of [18 F]FDG-PET/CT radiomic features with respect to tumor delineation in head and neck and pancreatic cancer patients. Physica Medica, 2018, 49, 105-111.	0.4	50
50	First application of a pixel-wise analysis on bladder dose–surface maps in prostate cancer radiotherapy. Radiotherapy and Oncology, 2016, 119, 123-128.	0.3	47
51	Detection of systematic errors in external radiotherapy before treatment delivery. Radiotherapy and Oncology, 1997, 45, 271-274.	0.3	46
52	Quality assurance by systematic in vivo dosimetry: results on a large cohort of patients. Radiotherapy and Oncology, 2000, 56, 85-95.	0.3	46
53	A two-variable linear model of parotid shrinkage during IMRT for head and neck cancer. Radiotherapy and Oncology, 2010, 94, 206-212.	0.3	43
54	Feasibility of an Adaptive Strategy in Preoperative Radiochemotherapy for Rectal Cancer With Image-Guided Tomotherapy: Boosting the Dose to the Shrinking Tumor. International Journal of Radiation Oncology Biology Physics, 2013, 87, 67-72.	0.4	43

#	Article	IF	CITATIONS
55	Relationships between bladder dose–volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer. Radiotherapy and Oncology, 2014, 111, 100-105.	0.3	43
56	Toxicity and efficacy of salvage carbon 11â€choline positron emission tomography/computed tomographyâ€guided radiation therapy in patients with lymph node recurrence of prostate cancer. BJU International, 2017, 119, 406-413.	1.3	43
57	Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. International Journal of Radiation Oncology Biology Physics, 2004, 59, 674-683.	0.4	42
58	NTCP Modeling of Subacute/Late Laryngeal Edema Scored by Fiberoptic Examination. International Journal of Radiation Oncology Biology Physics, 2009, 75, 915-923.	0.4	42
59	Feasibility of safe ultra-high (EQD ₂ >100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by Helical Tomotheraphy. Acta Oncológica, 2011, 50, 25-34.	0.8	42
60	Comparing 3-, 4- and 6-fields techniques for conformal irradiation of prostate and seminal vesicles using dose-volume histograms. Radiotherapy and Oncology, 1997, 44, 251-257.	0.3	41
61	A cylindrical model of the rectum: comparing dose–volume, dose–surface and dose–wall histograms in the radiotherapy of prostate cancer. Physics in Medicine and Biology, 2003, 48, 2603-2616.	1.6	41
62	Comparing 3DCRT and inversely optimized IMRT planning for head and neck cancer: Equivalence between step-and-shoot and sliding window techniques. Radiotherapy and Oncology, 2005, 77, 148-156.	0.3	41
63	Is It Time to Tailor the Prediction of Radio-Induced Toxicity in Prostate Cancer Patients? Building the First Set of Nomograms for Late Rectal Syndrome. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1957-1966.	0.4	41
64	Contouring Variability of the Penile Bulb on CT Images: Quantitative Assessment Using a Generalized Concordance Index. International Journal of Radiation Oncology Biology Physics, 2012, 84, 841-846.	0.4	41
65	Predictors of PEG dependence after IMRT±chemotherapy for oropharyngeal cancer. Radiotherapy and Oncology, 2013, 107, 300-304.	0.3	40
66	Hypofractionated adjuvant radiotherapy with helical Tomotherapy after radical prostatectomy: Planning data and toxicity results of a Phase l–II study. Radiotherapy and Oncology, 2008, 88, 26-33.	0.3	39
67	Predictive models of toxicity in external radiotherapy. Cancer, 2009, 115, 3135-3140.	2.0	39
68	Time course of hypothalamic-pituitary deficiency in adults receiving cranial radiotherapy for primary extrasellar brain tumors. Radiotherapy and Oncology, 2011, 99, 23-28.	0.3	39
69	Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: The case of previous abdominal surgery. Results from a prospective trial. Radiotherapy and Oncology, 2012, 103, 252-255.	0.3	39
70	Survival Following Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiotherapy in Patients With Prostate Cancer: The Impact of Competing Causes of Mortality and Patient Stratification. European Urology, 2013, 64, 557-564.	0.9	39
71	Late Fecal Incontinence After High-Dose Radiotherapy for Prostate Cancer: Better Prediction Using Longitudinal Definitions. International Journal of Radiation Oncology Biology Physics, 2012, 83, 38-45.	0.4	38
72	High-Dose Adjuvant Radiotherapy After Radical Prostatectomy With or Without Androgen Deprivation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 960-965.	0.4	38

#	Article	IF	Citations
73	Sparing the penile bulb in the radical irradiation of clinically localised prostate carcinoma: A comparison between MRI and CT prostatic apex definition in 3DCRT, Linac-IMRT and Helical Tomotherapy. Radiotherapy and Oncology, 2009, 93, 57-63.	0.3	37
74	Physics aspects of prostate tomotherapy: Planning optimization and image-guidance issues. Acta $Oncol\tilde{A}^3$ gica, 2008, 47, 1309-1316.	0.8	35
75	Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is ¹¹ C-Choline PET/CT Predictive of Survival Outcomes?. Journal of Nuclear Medicine, 2015, 56, 1836-1842.	2.8	35
76	In-vivo dosimetry by diode semiconductors in combination with portal films during TBI: reporting a 5-year clinical experience. Radiotherapy and Oncology, 1999, 52, 269-276.	0.3	34
77	Embracing Phenomenological Approaches to Normal Tissue Complication Probability Modeling: A Question of Method. International Journal of Radiation Oncology Biology Physics, 2015, 91, 468-471.	0.4	34
78	PET textural features stability and pattern discrimination power for radiomics analysis: An "ad-hoc― phantoms study. Physica Medica, 2018, 50, 66-74.	0.4	34
79	External Validation of Early Regression Index (ERITCP) as Predictor of Pathologic Complete Response in Rectal Cancer Using Magnetic Resonance-Guided Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1347-1356.	0.4	34
80	Predictive models of toxicity with external radiotherapy for prostate cancer. Cancer, 2009, 115, 3141-3149.	2.0	33
81	Grand challenges for medical physics in radiation oncology. Radiotherapy and Oncology, 2020, 153, 7-14.	0.3	33
82	Helical tomotherapy and intensity modulated proton therapy in the treatment of early stage prostate cancer: A treatment planning comparison. Radiotherapy and Oncology, 2011, 98, 74-80.	0.3	32
83	PET-guided dose escalation tomotherapy in malignant pleural mesothelioma. Strahlentherapie Und Onkologie, 2011, 187, 736-743.	1.0	31
84	Long term rectal function after high-dose prostatecancer radiotherapy: Results from a prospective cohort study. Radiotherapy and Oncology, 2014, 110, 272-277.	0.3	30
85	Daily Sodium Butyrate Enema for the Prevention of Radiation Proctitis in Prostate Cancer Patients Undergoing Radical Radiation Therapy: Results of a Multicenter Randomized Placebo-Controlled Dose-Finding Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 518-524.	0.4	29
86	Multi-variable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer: Results of a cohort study. Radiotherapy and Oncology, 2015, 116, 185-191.	0.3	29
87	A TCP-based early regression index predicts the pathological response in neo-adjuvant radio-chemotherapy of rectal cancer. Radiotherapy and Oncology, 2018, 128, 564-568.	0.3	28
88	Density variation of parotid glands during IMRT for head–neck cancer: Correlation with treatment and anatomical parameters. Radiotherapy and Oncology, 2012, 104, 224-229.	0.3	27
89	Modelling the Impact of Fractionation on Late Urinary Toxicity After Postprostatectomy Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1250-1257.	0.4	27
90	Anatomic Variations Due to Radical Prostatectomy. Strahlentherapie Und Onkologie, 2004, 180, 563-572.	1.0	26

#	Article	IF	Citations
91	Static and rotational intensity modulated techniques for head-neck cancer radiotherapy: A planning comparison. Physica Medica, 2014, 30, 973-979.	0.4	26
92	Hematologic Toxicity in Patients Treated With Postprostatectomy Whole-Pelvis Irradiation With Different Intensity Modulated Radiation Therapy Techniques Is Not Negligible and Is Prolonged: Preliminary Results of a Longitudinal, Observational Study. International Journal of Radiation Oncology Biology Physics, 2016, 95, 690-695.	0.4	26
93	Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose–volume effects. Radiotherapy and Oncology, 2017, 124, 296-301.	0.3	26
94	Predictors of acute bowel toxicity in patients treated with IMRT whole pelvis irradiation after prostatectomy. Radiotherapy and Oncology, 2010, 97, 71-75.	0.3	25
95	Early changes of parotid density and volume predict modifications at the end of therapy and intensity of acute xerostomia. Strahlentherapie Und Onkologie, 2014, 190, 1001-1007.	1.0	25
96	A Comparative Evaluation of 3 Different Free-Form Deformable Image Registration and Contour Propagation Methods for Head and Neck MRI: The Case of Parotid Changes During Radiotherapy. Technology in Cancer Research and Treatment, 2017, 16, 373-381.	0.8	25
97	Characterisation of rectal motion during neo-adjuvant radiochemotherapy for rectal cancer with image-guided tomotherapy: Implications for adaptive dose escalation strategies. Acta Oncol \tilde{A}^3 gica, 2012, 51, 318-324.	0.8	24
98	The research versus clinical service role of medical physics. Radiotherapy and Oncology, 2015, 114, 285-288.	0.3	24
99	Parotid gland shrinkage during IMRT predicts the time to Xerostomia resolution. Radiation Oncology, 2015, 10, 19.	1.2	23
100	Variations of tumor control and rectum complication probabilities due to random set-up errors during conformal radiation therapy of prostate cancer. Radiotherapy and Oncology, 1997, 44, 259-263.	0.3	22
101	Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy. Radiotherapy and Oncology, 2016, 118, 92-98.	0.3	22
102	Ct radiomic features of pancreatic neuroendocrine neoplasms (panNEN) are robust against delineation uncertainty. Physica Medica, 2019, 57, 41-46.	0.4	22
103	Modeling set-up error by daily MVCT for prostate adjuvant treatment delivered in 20 fractions: Implications for the assessment of the optimal correction strategies. Radiotherapy and Oncology, 2009, 93, 246-252.	0.3	21
104	Anatomical and clinical predictors of acute bowel toxicity in whole pelvis irradiation for prostate cancer with Tomotherapy. Radiotherapy and Oncology, 2011, 101, 460-464.	0.3	21
105	Patient-reported urinary incontinence after radiotherapy for prostate cancer: Quantifying the dose–effect. Radiotherapy and Oncology, 2017, 125, 101-106.	0.3	21
106	Comprehensive Intra-Institution stepping validation of knowledge-based models for automatic plan optimization. Physica Medica, 2019, 57, 231-237.	0.4	21
107	Robustness of CT radiomic features against image discretization and interpolation in characterizing pancreatic neuroendocrine neoplasms. Physica Medica, 2020, 76, 125-133.	0.4	21
108	Conformal irradiation of concave-shaped PTVs in the treatment of prostate cancer by simple 1D intensity-modulated beams. Radiotherapy and Oncology, 2000, 55, 49-58.	0.3	20

#	Article	IF	CITATIONS
109	Inverse and forward optimization of one- and two-dimensional intensity-modulated radiation therapy-based treatment of concave-shaped planning target volumes: the case of prostate cancer. Radiotherapy and Oncology, 2003, 66, 185-195.	0.3	20
110	In-gantry or remote patient positioning? Monte Carlo simulations for proton therapy centers of different sizes. Radiotherapy and Oncology, 2012, 103, 18-24.	0.3	20
111	Understanding Urinary Toxicity after Radiotherapy for Prostate Cancer: First Steps Forward. Tumori, 2017, 103, 395-404.	0.6	20
112	Knowledge-based automatic optimization of adaptive early-regression-guided VMAT for rectal cancer. Physica Medica, 2020, 70, 58-64.	0.4	20
113	Introducing the Jacobian-volume-histogram of deforming organs: application to parotid shrinkage evaluation. Physics in Medicine and Biology, 2011, 56, 3301-3312.	1.6	19
114	Training and validation of a robust PET radiomic-based index to predict distant-relapse-free-survival after radio-chemotherapy for locally advanced pancreatic cancer. Radiotherapy and Oncology, 2020, 153, 258-264.	0.3	19
115	Skin dose measurements for head and neck radiotherapy. Medical Physics, 1992, 19, 1263-1266.	1.6	18
116	On-line exit dose profile measurements by a diode linear array. Physics in Medicine and Biology, 1996, 41, 1291-1304.	1.6	18
117	Correlation between surrogates of bladder dosimetry and dose–volume histograms of the bladder wall defined on MRI in prostate cancer radiotherapy. Radiotherapy and Oncology, 2012, 105, 180-183.	0.3	18
118	Predictors of radio-induced visual impairment after radiosurgery for uveal melanoma. British Journal of Ophthalmology, 2018, 102, 833-839.	2.1	18
119	Agreement criteria between expected and measured field fluences in IMRT of head and neck cancer: The importance and use of the \hat{I}^3 histograms statistical analysis. Radiotherapy and Oncology, 2007, 85, 399-406.	0.3	17
120	Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning. Radiation Oncology, 2011, 6, 123.	1.2	17
121	Accuracy of dose calculation algorithms for static and rotational IMRT of lung cancer: A phantom study. Physica Medica, 2015, 31, 382-390.	0.4	17
122	Assessment and clinical validation of margins for adaptive simultaneous integrated boost in neo-adjuvant radiochemotherapy for rectal cancer. Physica Medica, 2015, 31, 167-172.	0.4	17
123	Could early tumour volume changes assessed on morphological MRI predict the response to chemoradiation therapy in locally-advanced rectal cancer?. Clinical Radiology, 2018, 73, 555-563.	0.5	17
124	Skin DVHs predict cutaneous toxicity in Head and Neck Cancer patients treated with Tomotherapy. Physica Medica, 2019, 59, 133-141.	0.4	17
125	Local dose analysis to predict acute and late urinary toxicities after prostate cancer radiotherapy: Assessment of cohort and method effects. Radiotherapy and Oncology, 2020, 147, 40-49.	0.3	17
126	A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy. Radiotherapy and Oncology, 2007, 82, 30-37.	0.3	16

#	Article	IF	CITATIONS
127	Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: A treament planning comparison. Radiotherapy and Oncology, 2013, 107, 207-212.	0.3	16
128	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in ≥PT2, pNO Patients With a Comprehensive Tumor Control Probability Model. International Journal of Radiation Oncology Biology Physics, 2016, 96, 333-340.	0.4	16
129	Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach. Cancers, 2021, 13, 4938.	1.7	16
130	Expanding the scientific role of medical physics in radiotherapy: Time to act. Radiotherapy and Oncology, 2015, 117, 401-402.	0.3	15
131	Patterns in ano-rectal dose maps and the risk of late toxicity after prostate IMRT. Acta Oncol \tilde{A}^3 gica, 2019, 58, 1757-1764.	0.8	15
132	Evaluation of an Early Regression Index (ERITCP) as Predictor of Pathological Complete Response in Cervical Cancer: A Pilot-Study. Applied Sciences (Switzerland), 2020, 10, 8001.	1.3	15
133	Skin-sparing reduction effects of thermoplastics used for patient immobilization in head and neck radiotherapy. Radiotherapy and Oncology, 1994, 30, 267-270.	0.3	14
134	Development of a Ready-to-Use Graphical Tool Based on Artificial Neural Network Classification: Application for the Prediction of Late Fecal Incontinence After Prostate Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1533-1542.	0.4	14
135	Predicting Late Fecal Incontinence Risk After Radiation Therapy for Prostate Cancer: New Insights From External Independent Validation. International Journal of Radiation Oncology Biology Physics, 2018, 102, 127-136.	0.4	14
136	Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases. British Journal of Radiology, 2020, 93, 20190353.	1.0	14
137	Spatial descriptions of radiotherapy dose: normal tissue complication models and statistical associations. Physics in Medicine and Biology, 2021, 66, 12TR01.	1.6	14
138	Long-term biochemical control of prostate cancer after standard or hyper-fractionation: Evidence for different outcomes between low–intermediate and high risk patients. Radiotherapy and Oncology, 2011, 101, 454-459.	0.3	13
139	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. European Urology, 2018, 74, 134-137.	0.9	13
140	Could perfusion heterogeneity at dynamic contrast-enhanced MRI be used to predict rectal cancer sensitivity to chemoradiotherapy?. Clinical Radiology, 2018, 73, 911.e1-911.e7.	0.5	13
141	Impact of the radiotherapy technique on the correlation between dose–volume histograms of the bladder wall defined on MRI imaging and dose–volume/surface histograms in prostate cancer patients. Physics in Medicine and Biology, 2013, 58, N115-N123.	1.6	12
142	Accurate outcome prediction after neo-adjuvant radio-chemotherapy for rectal cancer based on a TCP-based early regression index. Clinical and Translational Radiation Oncology, 2019, 19, 12-16.	0.9	12
143	Modelling Radiotherapy Side Effects. , 0, , .		12
144	Baseline status and dose to the penile bulb predict impotence 1Âyear after radiotherapy for prostate cancer. Strahlentherapie Und Onkologie, 2016, 192, 297-304.	1.0	10

#	Article	IF	CITATIONS
145	Salvage reirradiation for local failure of prostate cancer after curative radiation therapy: Association of rectal toxicity with dose distribution and normal-tissue complication probability models. Advances in Radiation Oncology, 2018, 3, 673-681.	0.6	10
146	A simple and robust method for in vivo midline dose map estimations using diodes and portal detectors. Radiotherapy and Oncology, 2001, 58, 169-178.	0.3	9
147	Quality assurance of 3D-CRT: Indications and difficulties in their applications. Critical Reviews in Oncology/Hematology, 2009, 70, 24-38.	2.0	9
148	[¹¹ C]choline-PET-guided Helical Tomotherapy and Estramustine in a Patient with Pelvic-Recurrent Prostate Cancer: Local Control and Toxicity Profile after 24 Months. Tumori, 2010, 96, 613-617.	0.6	9
149	Clinical Implementation of Knowledge-Based Automatic Plan Optimization for Helical Tomotherapy. Practical Radiation Oncology, 2021, 11 , e236-e244.	1.1	9
150	FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2071-2078.	3.3	8
151	Moderately Hypofractionated Helical IMRT, FDG–PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs. Clinical Lung Cancer, 2019, 20, e29-e38.	1.1	8
152	Pre-clinical Research on Bladder Toxicity After Radiotherapy for Pelvic Cancers: State-of-the Art and Challenges. Frontiers in Oncology, 2020, 10, 527121.	1.3	8
153	An Automatic Approach for Individual HU-Based Characterization of Lungs in COVID-19 Patients. Applied Sciences (Switzerland), 2021, 11, 1238.	1.3	8
154	Megavoltage CT Images of Helical Tomotherapy Unit for Radiation Treatment Simulation: Impact on Feasibility of Treatment Planning in a Prostate Cancer Patient with Bilateral Femoral Prostheses. Tumori, 2011, 97, 221-224.	0.6	7
155	The promise of adaptive radiotherapy for pelvic tumors: "too high cost for too little resultâ€or "a low cost for a significant resultâ€?. Acta Oncológica, 2016, 55, 939-942.	0.8	7
156	Predictors of 2-Year Incidence of Patient-Reported Urinary Incontinence After Post-prostatectomy Radiotherapy: Evidence of Dose and Fractionation Effects. Frontiers in Oncology, 2020, 10, 1207.	1.3	7
157	Virtual Tangential-fields Arc Therapy (ViTAT) for whole breast irradiation: Technique optimization and validation. Physica Medica, 2020, 77, 160-168.	0.4	7
158	Residual intra-fraction error in robotic spinal stereotactic body radiotherapy without immobilization devices. Physics and Imaging in Radiation Oncology, 2020, 16, 20-25.	1.2	7
159	Ten Year Results of Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer. Cancers, 2021, 13, 4970.	1.7	7
160	Development of a computer-controlled moving bar (CCMB) conformal technique for neck irradiation. Radiotherapy and Oncology, 1993, 27, 167-170.	0.3	6
161	Fractionation and late rectal toxicity: No reliable estimates of α∫β value for rectum can be derived from studies where different volumes of rectum are irradiated at different dose levels: In regard to Brenner (Int J Radiat Oncol Biol Phys 2004;60:1013–1015.). International Journal of Radiation Oncology Biology Physics. 2005, 62, 289-290.	0.4	6
162	Replacing Manual Planning of Whole Breast Irradiation With Knowledge-Based Automatic Optimization by Virtual Tangential-Fields Arc Therapy. Frontiers in Oncology, 2021, 11, 712423.	1.3	6

#	Article	IF	CITATIONS
163	Predicting pathological response after radio-chemotherapy for rectal cancer: Impact of late oxaliplatin administration. Radiotherapy and Oncology, 2020, 149, 174-180.	0.3	6
164	Knowledge-based automatic plan optimization for left-sided whole breast tomotherapy. Physics and Imaging in Radiation Oncology, 2022, 23, 54-59.	1.2	6
165	Cable-induced effects on plane-parallel ionization chamber measurements in large clinical electron beams. Medical Dosimetry, 1994, 19, 73-76.	0.4	5
166	Optimizing the movement of a single absorber for 1D non-uniform dose delivery by (fast) simulated annealing. Physics in Medicine and Biology, 1997, 42, 107-121.	1.6	5
167	Quality Control by Portal Film Analysis in Radiotherapy for Prostate Cancer: A Comparison between Two Different Institutions and Treatment Techniques. Tumori, 1998, 84, 640-648.	0.6	5
168	Characterization of volume and shape modifications of PET-positive nodes during Tomotherapy for head and neck cancer as assessed by MVCTs. Radiotherapy and Oncology, 2015, 115, 50-55.	0.3	5
169	The role of medical physics in prostate cancer radiation therapy. Physica Medica, 2016, 32, 435-437.	0.4	5
170	Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study. Radiotherapy and Oncology, 2021, 158, 74-82.	0.3	5
171	Helical Tomotherapy for Scalp Recurrence of Primary Eccrine Mucinous Adenocarcinoma. Tumori, 2009, 95, 832-835.	0.6	4
172	Oncology Scanâ€"The Vision of Medical Physics. International Journal of Radiation Oncology Biology Physics, 2014, 88, 251-253.	0.4	4
173	Early volume variation of positive lymph nodes assessed by in-room mega voltage CT images predicts risk of loco-regional relapses in head and neck cancer patients treated with intensity-modulated radiotherapy. Acta Oncológica, 2015, 54, 1490-1495.	0.8	4
174	Salvage Radiation Therapy for Increasing Prostate-Specific Antigen After Radical Prostatectomy: Who, When, and How?. Journal of Clinical Oncology, 2017, 35, 469-470.	0.8	4
175	Robust prediction of mortality of COVID-19 patients based on quantitative, operator-independent, lung CT densitometry. Physica Medica, 2021, 85, 63-71.	0.4	4
176	Toxicity of Hypofractionated Whole Breast Radiotherapy Without Boost and Timescale of Late Skin Responses in a Large Cohort of Early-Stage Breast Cancer Patients. Clinical Breast Cancer, 2022, 22, e480-e487.	1.1	4
177	Artificial intelligence applied to medicine: There is an "elephant in the room― Physica Medica, 2022, 98, 8-10.	0.4	4
178	Dose calculation and dosimetry tests for clinical implementation of 1D tissue-deficit compensation by a single dynamic absorber. Radiotherapy and Oncology, 1998, 47, 53-62.	0.3	3
179	Set-up error for conformal radiotherapy of prostate cancer. Radiotherapy and Oncology, 2000, 56, 355.	0.3	3
180	An automatic deformable registration method to evaluate parotid glands shrinkage during radiotherapy treatment in tomotherapy., 2009, 2009, 94-7.		3

#	Article	IF	CITATIONS
181	A non-invasive ultrasound imaging method to measure acute radiation-induced bladder wall thickening in rats. Radiation Oncology, 2020, 15, 240.	1.2	3
182	FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes. Current Radiopharmaceuticals, 2017, 10, 102-110.	0.3	3
183	Implementation of automatic plan optimization in Italy: Status and perspectives. Physica Medica, 2021, 92, 86-94.	0.4	3
184	Irradiation Fields and Doses in Glioblastoma Multiforme: Are Current Standards Adequate?. Tumori, 2001, 87, 85-90.	0.6	2
185	Re: Mark K. Buyyounouski. Radiobiological Modeling and the Study of Hypofractionated Radiotherapy for Prostate Cancer. Eur Urol 2014;66:1031–2. European Urology, 2015, 67, e56-e57.	0.9	2
186	In Regard to Lewis et al. International Journal of Radiation Oncology Biology Physics, 2016, 94, 859-860.	0.4	2
187	Re: Daniel E. Spratt, Herbert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71;37–43. European Urology, 2017, 71, e179-e180.	0.9	2
188	Salvage radiation therapy after prostatectomy: Understanding the dose–response effect. Radiotherapy and Oncology, 2017, 123, 486-487.	0.3	2
189	Skin dose calculation during radiotherapy of head and neck cancer using deformable image registration of planning and mega-voltage computed tomography scans. Physics and Imaging in Radiation Oncology, 2018, 8, 44-50.	1.2	2
190	Clinical implementation of low-dose total body irradiation using topotherapy technique. Physics and Imaging in Radiation Oncology, 2019, 12, 74-79.	1.2	2
191	Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer patients. Scientific Reports, 2020, 10, 14613.	1.6	2
192	Predictors of Patient-Reported Incontinence at Adjuvant/Salvage Radiotherapy after Prostatectomy: Impact of Time between Surgery and Radiotherapy. Cancers, 2021, 13, 3243.	1.7	2
193	Oligometastatic disease in prostate cancer, a continuously changing paradigm: patient selection and treatment strategy. Translational Cancer Research, 2017, 6, S112-S116.	0.4	2
194	Second Tumor Induction Risk in IMRT for Prostate Cancer. Health Physics, 2015, 109, 549-555.	0.3	1
195	Dose Escalation in Salvage Radiation Therapy and Urinary Toxicity: A Small Price to Pay for a Significant Prospective Benefit. Journal of Clinical Oncology, 2016, 34, 1704-1705.	0.8	1
196	In Regard to Pommier et al. International Journal of Radiation Oncology Biology Physics, 2017, 97, 1109-1110.	0.4	1
197	On the original article by Ehsan Samei and Thomas Grist "Why physics in medicine―firstly published on the Journal of American College of Radiology (2018). Physica Medica, 2019, 64, 317-318.	0.4	1
198	In Reply to Loganadane etÂal. International Journal of Radiation Oncology Biology Physics, 2019, 103, 777-778.	0.4	1

#	Article	IF	CITATIONS
199	Early variation of 18-fluorine-labelled fluorodeoxyglucose PET-derived parameters after chemoradiotherapy as predictors of survival in locally advanced pancreatic carcinoma patients. Nuclear Medicine Communications, 2019, 40, 1072-1080.	0.5	1
200	Editorial: Modeling for Prediction of Radiation-Induced Toxicity to Improve Therapeutic Ratio in the Modern Radiation Therapy Era. Frontiers in Oncology, 2021, 11 , 690649.	1.3	1
201	In Regard to Wages et al and Leite et al. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1548-1549.	0.4	1
202	The scientific publications of AIFM members in 2015–2019: A survey of the FutuRuS working group. Physica Medica, 2021, 88, 111-116.	0.4	1
203	In response to Dr. G. Bauman and Dr. G. Rodrigues. International Journal of Radiation Oncology Biology Physics, 2004, 59, 914-915.	0.4	0
204	The Monte Carlo method for the evaluation of automatic recontouring algorithms accuracy. , 2010, , .		0
205	Erratum to "Time course of hypothalamic-pituitary deficiency in adults receiving cranial radiotherapy for primary extrasellar brain tumors―[Radiother. Oncol. 99 (2011) 23–28]. Radiotherapy and Oncology, 2012, 104, 408.	0.3	0
206	Reply to Berardino De Bari, Filippo Alongi, Stefano Arcangeli's Letter to the Editor re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected Severe (Grade 3–4) Late Urinary Toxicity After Postprostatectomy Hypofractionated Radiotherapy: A Single-institution Analysis of 1176 Patients. Eur Urol 2014;66:1024–30. European Urology, 2014, 66, e113-e114.	0.9	0
207	Analysis of serial CT images for studying the RT effects in head-neck cancer patients. , 2015, 2015, 5235-8.		О
208	Salvage radiotherapy for patients with rising PSA. Lancet Oncology, The, 2016, 17, e314-e315.	5.1	0
209	Reply to Salvador Vale's Letter to the Editor re: Cesare Cozzarini. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment? Eur Urol 2017;71:44–5. Preclinical Combinatory Approach to Enhance Radiotherapy Effects and Reduce its Morbidity may be Tested in the	0.9	0
210	Monitoring skin dose changes during image-guided helical tomotherapy for head and neck cancer patients. Strahlentherapie Und Onkologie, 2020, 196, 243-251.	1.0	0
211	In reply to the letter to the editor: "In reply to Fiorino et al: The central role of the radiation oncologist in the multidisciplinary and multiprofessional model of modern radiation therapy― Radiotherapy and Oncology, 2021, 155, e22-e23.	0.3	0
212	A simple and robust method for clinical implementation of midplane transit dosimetry using diodes and portal films. , 2000, , 397-398.		0
213	Data driven approaches I: conventional statistical inference methods, including linear and logistic regression., 2018,, 85-127.		0
214	Predicting Toxicity in External Radiotherapy. , 2019, , 337-363.		0